DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cataflam (Diclofenac Potassium) - Summary

 

-- advertisement --

Cardiovascular Risk

•      NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS).

•      Cataflam® (diclofenac potassium immediate-release tablets) is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).

Gastrointestinal Risk

•      NSAIDs cause an increased risk of serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS).

 

CATAFLAM SUMMARY

Cataflam®

Cataflam® (diclofenac potassium immediate-release tablets), is a benzeneacetic acid derivative. Cataflam is available as immediate-release Tablets of 50 mg (light brown) for oral administration. The chemical name is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monopotassium salt.

Cataflam® (diclofenac potassium immediate-release tablets) is indicated:

  • For treatment of primary dysmenorrhea
  • For relief of mild to moderate pain
  • For relief of signs and symptoms of osteoarthritis
  • For relief of signs and symptoms of rheumatoid arthritis

CATAFLAM NEWS HIGHLIGHTS

Media Articles Related to Cataflam (Diclofenac)

diclofenac and misoprostol, Arthrotec
Source: MedicineNet meloxicam Specialty [2005.12.13]

more>>

Published Studies Related to Cataflam (Diclofenac)

Diclofenac sodium and occlusal splint therapy in TMJ osteoarthritis: a randomized controlled trial. [2008.05.09]

Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). [2008.03]

Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. [2008.03]

Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. [2008.03]

Efficacy of lornoxicam for acute postoperative pain relief after septoplasty: a comparison with diclofenac, ketoprofen, and dipyrone. [2008.03]

more>>

Clinical Trials Related to Cataflam (Diclofenac)

Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses)Versus Oral Diclofenac Potassium [Completed]

Assess Platelet Function and Safety After Administration of Injectable Diclofenac Compared to Ketorolac and Aspirin in Adult Male Volunteers [Completed]

Diclofenac Patch for Treatment of Mild to Moderate Ankle Sprain [Active, not recruiting]

Diclofenac Patch for Treatment of Mild to Moderate Tendonitis or Bursitis [Completed]

Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis [Completed]

more>>

Page last updated: 2008-06-22

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008